

HOLLIS EDEN PHARMACEUTICALS INC /DE/

Form 8-K

September 24, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 24, 2002

HOLLIS-EDEN PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other	000-24672 (Commission	13-3697002 (IRS Employer
jurisdiction of incorporation)	File No.)	Identification No.)

4435 Eastgate Mall, Suite 400

San Diego, California 92121

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (858) 587-9333

Item 5. Other Events and Required FD Disclosure.

On September 10, 2003, Hollis-Eden Pharmaceuticals, Inc. (the Company) presented at the Roth Capital Partners New York Conference. A copy of the Company s presentation is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

<u>Number</u>	<u>Description</u>
99.1	Presentation delivered by the Company on September 10, 2003.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: September 24, 2003

By:

/s/ ERIC J. LOUMEAU

Eric J. Loumeau
Vice President,

General Counsel and Secretary

INDEX TO EXHIBITS

99.1 Presentation delivered by the Company on September 10, 2003.